JP2015000064A5 - - Google Patents

Download PDF

Info

Publication number
JP2015000064A5
JP2015000064A5 JP2014123573A JP2014123573A JP2015000064A5 JP 2015000064 A5 JP2015000064 A5 JP 2015000064A5 JP 2014123573 A JP2014123573 A JP 2014123573A JP 2014123573 A JP2014123573 A JP 2014123573A JP 2015000064 A5 JP2015000064 A5 JP 2015000064A5
Authority
JP
Japan
Prior art keywords
subject
hematopoietic stem
bone marrow
progenitor cells
primary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014123573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015000064A (ja
JP6532653B2 (ja
Filing date
Publication date
Priority claimed from US13/919,241 external-priority patent/US9428748B2/en
Application filed filed Critical
Publication of JP2015000064A publication Critical patent/JP2015000064A/ja
Publication of JP2015000064A5 publication Critical patent/JP2015000064A5/ja
Application granted granted Critical
Publication of JP6532653B2 publication Critical patent/JP6532653B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014123573A 2013-06-17 2014-06-16 造血幹細胞の増殖方法 Active JP6532653B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/919,241 2013-06-17
US13/919,241 US9428748B2 (en) 2013-06-17 2013-06-17 Method of expanding hematopoietic stem cells

Publications (3)

Publication Number Publication Date
JP2015000064A JP2015000064A (ja) 2015-01-05
JP2015000064A5 true JP2015000064A5 (enExample) 2017-08-03
JP6532653B2 JP6532653B2 (ja) 2019-06-19

Family

ID=50942591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014123573A Active JP6532653B2 (ja) 2013-06-17 2014-06-16 造血幹細胞の増殖方法

Country Status (6)

Country Link
US (1) US9428748B2 (enExample)
EP (1) EP2816107B1 (enExample)
JP (1) JP6532653B2 (enExample)
DK (1) DK2816107T3 (enExample)
ES (1) ES2757508T3 (enExample)
HU (1) HUE046356T2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL260987B2 (en) * 2016-02-04 2024-09-01 Zhenglun Zhu Treatment and diagnosis of inflammatory disorders
GB201608944D0 (en) * 2016-05-20 2016-07-06 Ospedale San Raffaele And Fond Telethon Gene Tharapy
JP7891314B2 (ja) 2020-05-06 2026-07-16 セレクティス ソシエテ アノニム 治療用タンパク質の送達のために細胞を遺伝子改変する方法
WO2021224395A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
JP2003527096A (ja) * 1999-10-07 2003-09-16 エイブイアイ バイオファーマ， インコーポレイテッド Ｃ−ｍｙｃアンチセンス処理した造血幹細胞組成物および方法
KR20050115231A (ko) * 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
EP1601759A4 (en) * 2003-03-07 2007-02-14 Gamida Cell Ltd EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING PI-3 KINASE MODULATORS
EP2612675A1 (en) 2006-02-22 2013-07-10 Zhenglun Zhu Treatment of development-related disorders
EP1999255A2 (en) * 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
HUE042736T2 (hu) * 2009-07-15 2019-07-29 Zhenglun Zhu Gyulladásos vagy autoimmun rendellenességek kezelésének irányítása HOM-1 kifejezés alkalmazásával
WO2011028819A1 (en) * 2009-09-01 2011-03-10 The Trustees Of Columbia University In The City Of New York Synergistic transcription modules and uses thereof
CN103415615B (zh) 2010-11-24 2015-11-25 高红 扩增造血干细胞
WO2012170979A1 (en) 2011-06-10 2012-12-13 Zhenglun Zhu Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof
CN104024854A (zh) * 2011-09-11 2014-09-03 奥拉森斯有限责任公司 细胞摄取对照系统
JP6559117B2 (ja) * 2013-04-10 2019-08-14 ツェンルン チュー ヒト樹状細胞の分化および成熟を調節するホメオボックス転写因子ＶｅｎｔＸ

Similar Documents

Publication Publication Date Title
MX384315B (es) Agente para el tratamiento y/o prevención de enfermedades asociadas con anormalidades inmunes.
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
JP2014240404A5 (enExample)
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
NZ739448A (en) Transgene genetic tags and methods of use
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
EP4272757A3 (en) Modified nk-92 cells for treating cancer
JP2018522041A5 (enExample)
HRP20240798T1 (hr) Terapija matičnim stanicama kod patologija endometrija
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
JP2015517520A5 (enExample)
JP2016515123A5 (enExample)
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο
JP2015044878A5 (enExample)
WO2016066722A3 (en) Bacteriophage combinations for human or animal therapy
MD20180049A2 (ro) Compoziţie farmaceutică
WO2015114633A8 (en) Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same